Skip to main content
. 2017 May;14(2):162–175. doi: 10.20892/j.issn.2095-3941.2017.0020

S2.

Genotype and allele of ApaI, VDR-polymorphism, and BsmI-ApaI, ApaI-TaqI, BsmI-ApaI-TaqI combined genotypes of 74 melanoma patients and comparisons between groups of 100% VDR-positive cells (n=12) vs. <100% ( n=62); over the median (>20%) VDR-positive cells (n=36) vs. below or equal the median (≤20%) (n=38); and absence of VDR-positive cell (n=15) vs. remaining cases with detected VDR expression (n=59)

VDR genotype or combined genotype All melanoma patients (n=74) 100% VDR-positive cells (n=12) <100% VDR-positive cells (n=62) OR (CI) 100% vs. <100% VDR-positive P=100% vs. <100% VDR-positive >20%a VDR-positive cells (n=36) ≤20% VDR-positive cells (n=38) OR (CI)>20%vs. ≤20% VDR-positive P>20%vs.≤20% VDR-positive VDR absence (0% positive)(n=15) VDR presence (>0% positive)(n=59) OR (CI) VDR absencevs. presence PVDR absence vs. presence
ApaI genotype
AA 30 (40.5) 8 (66.7) 22 (35.5) 3.64 (0.98–13.5) 0.058 13 (36.1) 17 (44.7) 0.70 (0.27–1.78) 0.450 8 (53.3) 22 (37.3) 1.92 (0.61–6.03) 0.258
Aa 36 (48.6) 4 (33.3) 32 (51.6) 0.47 (0.13–1.72) 0.246 22 (61.1) 14 (36.8) 2.69 (1.05–6.90) 0.037 5 (33.3) 31 (52.5) 0.45 (0.14–1.48) 0.184
aa 8 (10.8) 0 (–) 8 (12.9) b 0.339 1 (2.8) 7 (18.4) 0.13 (0.01–1.09) 0.056 2 (13.3) 6 (10.2) 1.36 (0.24–7.52) 0.660
A allele 96/148 (64.9) 20/24 (83.3) 76/124 (61.3) 3.16 (1.02–9.80) 0.038 48/72 (66.7) 48/76 (63.2) 1.17 (0.59–2.29) 0.655 21/30 (70.0) 75/118 (63.6) 1.34 (0.56–3.18) 0.509
a allele 52/148 (35.1) 4/24 (16.7) 48/124 (38.7) 0.32 (0.10–0.98) 0.038 24/72 (33.3) 28/76 (36.8) 0.86 (0.44–1.69) 0.655 9/30 (30.0) 43/118 (36.4) 0.75 (0.31–1.78) 0.509
BsmI-ApaI combined genotype
BBAA 23 (31.1) 5 (41.7) 18 (29.0) 1.75 (0.49–6.23) 0.498 9 (25.0) 14 (36.8) 0.57 (0.21–1.56) 0.271 6 (40.0) 17 (28.8) 1.65 (0.51–5.34) 0.533
BbAA 5 (6.8) 3 (25.0) 2 (3.2) 10.0 (1.46–68.3) 0.028 4 (11.1) 1 (2.6) 4.62 (0.49–43.5) 0.194 1 (6.7) 4 (6.8) 0.98 (0.10–9.49) 1.000
BbAa 31 (41.9) 1 (8.3) 30 (48.4) 0.10 (0.01–0.80) 0.010 18 (50.0) 13 (34.2) 1.92 (0.75–4.90) 0.169 5 (33.3) 26 (44.1) 0.63 (0.19–2.09) 0.452
Bbaa 2 (2.7) 0 (–) 2 (3.2) b 1.000 0 (–) 2 (5.3) b 0.494 0 (–) 2 (3.4) b 1.000
bbAA 2 (2.7) 0 (–) 2 (3.2) b 1.000 0 (–) 2 (5.3) b 0.494 1 (6.7) 1 (1.7) 4.14 (0.24–70.4) 0.367
bbAa 5 (6.8) 3 (25.0) 2 (3.2) 10.0 (1.46–68.3) 0.028 4 (11.1) 1 (2.6) 4.62 (0.49–43.5) 0.194 0 (–) 5 (8.5) b 0.576
bbaa 6 (8.1) 0 (–) 6 (9.7) b 0.581 1 (2.8) 5 (13.2) 0.19 (0.02–1.70) 0.200 2 (13.3) 4 (6.8) 2.11 (0.35–12.8) 0.595
ApaI-TaqI combined genotype
AATT 4 (5.4) 0 (–) 4 (6.5) b 1.000 0 (–) 4 (10.5) b 0.115 3 (20.0) 1 (1.7) 14.5 (1.39–152) 0.025
AATt 14 (18.9) 6 (50.0) 8 (12.9) 6.75 (1.74–26.1) 0.008 9 (25.0) 5 (13.2) 2.20 (0.66–7.35) 0.194 4 (26.7) 10 (16.9) 1.78 (0.47–6.74) 0.463
AAtt 12 (16.2) 2 (16.7) 10 (16.1) 1.04 (0.20–5.48) 1.000 4 (11.1) 8 (21.1) 0.47 (0.13–1.72) 0.246 1 (6.7) 11 (18.6) 0.31 (0.04–2.63) 0.439
AaTT 12 (16.2) 3 (25.0) 9 (14.5) 1.96 (0.44–8.67) 0.399 9 (25.0) 3 (7.9) 3.89 (0.96–15.8) 0.046 1 (6.7) 11 (18.6) 0.31 (0.04–2.63) 0.439
AaTt 24 (32.4) 1 (8.3) 23 (37.1) 0.15 (0.02–1.27) 0.089^ 13 (36.1) 11 (28.9) 1.39 (0.52–3.68) 0.511 4 (26.7) 20 (33.9) 0.71 (0.20–2.51) 0.761
aaTT 8 (10.8) 0 (–) 8 (12.9) b 0.339 1 (2.8) 7 (18.4) 0.13 (0.01–1.09) 0.056 2 (13.3) 6 (10.2) 1.36 (0.24–7.52) 0.660
BsmI-ApaI-TaqI combined genotype
BBAATT 1 (1.4) 0 (–) 1 (1.6) b 1.000 0 (–) 1 (2.6) b 1.000 1 (6.7) 0 (–) b 0.203
BBAATt 10 (13.5) 3 (25.0) 7 (11.3) 2.62 (0.57–12.0) 0.351 5 (13.9) 5 (13.2) 1.06 (0.28–4.04) 1.000 4 (26.7) 6 (10.2) 3.21 (0.77–13.3) 0.110
Continued